Heron Therapeutics (HRTX) Competitors

$0.87 0.00 (-0.14%)

As of 01:02 PM Eastern

HRTX vs. GYRE, ACRS, CTMX, ZVRA, and CYRX

Should you buy Heron Therapeutics stock or one of its competitors? MarketBeat compares Heron Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Heron Therapeutics include Gyre Therapeutics (GYRE), Aclaris Therapeutics (ACRS), CytomX Therapeutics (CTMX), Zevra Therapeutics (ZVRA), and CryoPort (CYRX). These companies are all part of the "pharmaceutical products" industry.

How does Heron Therapeutics compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Gyre Therapeutics presently has a consensus target price of $17.00, suggesting a potential upside of 179.88%. Heron Therapeutics has a consensus target price of $4.50, suggesting a potential upside of 417.24%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Heron Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Gyre Therapeutics had 2 more articles in the media than Heron Therapeutics. MarketBeat recorded 3 mentions for Gyre Therapeutics and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.87 beat Gyre Therapeutics' score of -0.32 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Heron Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 10.0% of Gyre Therapeutics shares are held by insiders. Comparatively, 5.9% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Gyre Therapeutics has a net margin of -5.44% compared to Heron Therapeutics' net margin of -20.53%. Gyre Therapeutics' return on equity of 3.13% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

Gyre Therapeutics has higher earnings, but lower revenue than Heron Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	5.05	$5.03M	-$0.09	N/A
Heron Therapeutics	$150.71M	1.09	-$20.19M	-$0.18	N/A

Gyre Therapeutics has a beta of 2.03, meaning that its share price is 103% more volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market.

Summary

Gyre Therapeutics beats Heron Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Heron Therapeutics compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Aclaris Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market.

In the previous week, Aclaris Therapeutics had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 2 mentions for Aclaris Therapeutics and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.87 beat Aclaris Therapeutics' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Heron Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Heron Therapeutics has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	80.89	-$64.92M	-$0.56	N/A
Heron Therapeutics	$150.71M	1.09	-$20.19M	-$0.18	N/A

Heron Therapeutics has a net margin of -20.53% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

Aclaris Therapeutics presently has a consensus target price of $11.29, suggesting a potential upside of 148.86%. Heron Therapeutics has a consensus target price of $4.50, suggesting a potential upside of 417.24%. Given Heron Therapeutics' higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Heron Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 5.6% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 5.9% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Heron Therapeutics beats Aclaris Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Heron Therapeutics compare to CytomX Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

CytomX Therapeutics has lower revenue, but higher earnings than Heron Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$150.71M	1.09	-$20.19M	-$0.18	N/A
CytomX Therapeutics	$76.20M	8.50	-$17.37M	-$0.41	N/A

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 5.9% of Heron Therapeutics shares are owned by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, CytomX Therapeutics had 2 more articles in the media than Heron Therapeutics. MarketBeat recorded 3 mentions for CytomX Therapeutics and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.87 beat CytomX Therapeutics' score of 0.67 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heron Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Heron Therapeutics presently has a consensus target price of $4.50, indicating a potential upside of 417.24%. CytomX Therapeutics has a consensus target price of $12.10, indicating a potential upside of 218.00%. Given Heron Therapeutics' higher probable upside, equities analysts clearly believe Heron Therapeutics is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Heron Therapeutics has a net margin of -20.53% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

Heron Therapeutics has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market.

Summary

CytomX Therapeutics beats Heron Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Heron Therapeutics compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Zevra Therapeutics has higher earnings, but lower revenue than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	5.68	$83.23M	$1.99	5.14
Heron Therapeutics	$150.71M	1.09	-$20.19M	-$0.18	N/A

Zevra Therapeutics presently has a consensus price target of $23.33, suggesting a potential upside of 128.27%. Heron Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 417.24%. Given Heron Therapeutics' higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Heron Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Heron Therapeutics had 1 more articles in the media than Zevra Therapeutics. MarketBeat recorded 1 mentions for Heron Therapeutics and 0 mentions for Zevra Therapeutics. Heron Therapeutics' average media sentiment score of 0.87 beat Zevra Therapeutics' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Zevra Therapeutics	Neutral
Heron Therapeutics	Positive

Zevra Therapeutics has a net margin of 101.58% compared to Heron Therapeutics' net margin of -20.53%. Zevra Therapeutics' return on equity of 51.49% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 5.9% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Zevra Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market.

Summary

Zevra Therapeutics beats Heron Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Heron Therapeutics compare to CryoPort?

Heron Therapeutics (NASDAQ:HRTX) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

CryoPort has higher revenue and earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$150.71M	1.09	-$20.19M	-$0.18	N/A
CryoPort	$176.18M	3.99	$78.30M	$1.35	10.33

In the previous week, CryoPort had 3 more articles in the media than Heron Therapeutics. MarketBeat recorded 4 mentions for CryoPort and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.87 beat CryoPort's score of 0.43 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heron Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 5.9% of Heron Therapeutics shares are held by insiders. Comparatively, 10.0% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Heron Therapeutics has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

CryoPort has a net margin of 41.57% compared to Heron Therapeutics' net margin of -20.53%. CryoPort's return on equity of -7.92% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
CryoPort	41.57%	-7.92%	-4.79%

Heron Therapeutics presently has a consensus price target of $4.50, suggesting a potential upside of 417.24%. CryoPort has a consensus price target of $14.69, suggesting a potential upside of 5.32%. Given Heron Therapeutics' higher possible upside, equities research analysts clearly believe Heron Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
CryoPort	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Summary

CryoPort beats Heron Therapeutics on 14 of the 16 factors compared between the two stocks.

Get Heron Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HRTX vs. The Competition

Export

Metric	Heron Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$164.67M	$3.02B	$6.38B	$12.34B
Dividend Yield	N/A	1.96%	2.79%	5.33%
P/E Ratio	-4.83	17.77	20.91	25.65
Price / Sales	1.09	301.47	543.80	85.61
Price / Cash	N/A	57.57	44.13	56.16
Price / Book	21.75	4.59	10.09	7.06
Net Income	-$20.19M	$74.99M	$3.55B	$335.04M
7 Day Performance	2.35%	0.14%	4.71%	2.60%
1 Month Performance	-14.71%	-4.86%	1.43%	1.42%
1 Year Performance	-53.48%	35.48%	36.72%	35.67%

Heron Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HRTX Heron Therapeutics	2.4155 of 5 stars	$0.87 -0.1%	$4.50 +417.2%	-53.7%	$164.67M	$150.71M	N/A	300
GYRE Gyre Therapeutics	2.3612 of 5 stars	$7.16 +1.0%	$17.00 +137.4%	-40.4%	$694.45M	$116.59M	N/A	40
ACRS Aclaris Therapeutics	2.2574 of 5 stars	$4.88 -1.5%	$11.29 +131.4%	+251.9%	$683.22M	$7.83M	N/A	100
CTMX CytomX Therapeutics	3.0924 of 5 stars	$3.91 +1.2%	$12.78 +227.2%	+84.3%	$666.98M	$76.20M	N/A	170	Analyst Upgrade
ZVRA Zevra Therapeutics	3.5352 of 5 stars	$11.03 +2.2%	$23.33 +111.5%	+21.1%	$655.94M	$106.47M	5.58	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HRTX) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Heron Therapeutics (HRTX) Competitors

HRTX vs. GYRE, ACRS, CTMX, ZVRA, and CYRX

How does Heron Therapeutics compare to Gyre Therapeutics?

Summary

How does Heron Therapeutics compare to Aclaris Therapeutics?

Summary

How does Heron Therapeutics compare to CytomX Therapeutics?

Summary

How does Heron Therapeutics compare to Zevra Therapeutics?

Summary

How does Heron Therapeutics compare to CryoPort?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX vs. The Competition

Heron Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Heron Therapeutics (HRTX) Competitors

HRTX vs. GYRE, ACRS, CTMX, ZVRA, and CYRX

How does Heron Therapeutics compare to Gyre Therapeutics?

Do analysts rate GYRE or HRTX?

Does the media refer more to GYRE or HRTX?

Do institutionals and insiders hold more shares of GYRE or HRTX?

Is GYRE or HRTX more profitable?

Which has stronger valuation & earnings, GYRE or HRTX?

Which has more risk & volatility, GYRE or HRTX?

Summary

How does Heron Therapeutics compare to Aclaris Therapeutics?

Which has more volatility and risk, ACRS or HRTX?

Does the media refer more to ACRS or HRTX?

Which has preferable valuation and earnings, ACRS or HRTX?

Is ACRS or HRTX more profitable?

Do analysts recommend ACRS or HRTX?

Do insiders & institutionals hold more shares of ACRS or HRTX?

Summary

How does Heron Therapeutics compare to CytomX Therapeutics?

Which has better valuation & earnings, HRTX or CTMX?

Do insiders and institutionals have more ownership in HRTX or CTMX?

Does the media prefer HRTX or CTMX?

Do analysts prefer HRTX or CTMX?

Is HRTX or CTMX more profitable?

Which has more volatility and risk, HRTX or CTMX?

Summary

How does Heron Therapeutics compare to Zevra Therapeutics?

Which has stronger valuation and earnings, ZVRA or HRTX?

Do analysts rate ZVRA or HRTX?

Does the media refer more to ZVRA or HRTX?

Is ZVRA or HRTX more profitable?

Do institutionals & insiders have more ownership in ZVRA or HRTX?

Which has more risk & volatility, ZVRA or HRTX?

Summary

How does Heron Therapeutics compare to CryoPort?

Which has preferable valuation & earnings, HRTX or CYRX?

Does the media prefer HRTX or CYRX?

Do insiders & institutionals hold more shares of HRTX or CYRX?

Which has more volatility & risk, HRTX or CYRX?

Is HRTX or CYRX more profitable?

Do analysts rate HRTX or CYRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX vs. The Competition

Heron Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools